Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib. Safety is primarily based on dose limiting toxicity (DLT) evaluation at various dose levels (DL). The investigators believe that there is evidence in castrate resistant prostate cancer (CRPC) that two growth factor receptors (EGFR and Her 2/Neu) are increased in prostate cancer (PCa) cells. Both these receptors are turned off by the drug lapatinib. By adding lapatinib, the investigators hope that signaling from the receptors will be turned off and therefore make the participant's cancer more responsive to KHAD treatment.

Key facts

Study ID

NCT00953576

Run by

Dana-Farber Cancer Institute

People needed

11

Starts

2009-09-29

Expected to finish

2013-04-11

Last updated by the study team

2018-09-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with CRPC with metastatic bone disease. At least one site of metastatic disease must be amenable to a needle biopsy. Bone sites include lumbar vertebrae, pelvic bones and long bones. Excluded sites are thoracic, cervical vertebrae, skull and rib lesions
• Patients may have had a number of previous hormonal therapies including ketoconazole and abiraterone, provided these were discontinued >3 months before starting the trial
• Patients may have had any number of previous cytotoxic therapies
• Castrate resistant disease as defined by PSA working group. Patients must have a rise in PSA on two successive determinations at least one week apart and PSA levels 5ng/ml or greater and testosterone levels <50
• Adequate renal, hepatic and bone marrow function as outlined in protocol
• PTT< 60, INR <1.5NL unless on warfarin therapy
• > 6 month life expectancy
• At least a 4 week interval from previous treatment other than LHRH analog and bisphosphonates. Patients on bicalutamide must have discontinued this medication for at least 6 weeks to be eligible
• Patients receiving bisphosphonate can be maintained on this therapy
• No major surgery or radiation therapy within 4 weeks
• No strontium-89 or samarium-153 therapy within 4 weeks
• ECG showing normal QT interval
• No thromboembolism in past 6 months
• Age > 18 years
• Investigator must check current patient medications against the list of CYP3A4 inhibitors and inducers prior to registration
• Echocardiogram or MUGA demonstrating ejection fraction within institutional normal limits

You may not qualify if…

• No previous therapy with lapatinib
• No previous therapy with ketoconazole within 3 months of starting trial
• The use of complementary therapy directed at prostate cancer treatment excluding the following: green tea, commercial multivitamin preparations. Vitamin B complex, C, D, E and multivitamins are permitted if these are being taken at less than 3 times the RDA
• The concomitant use of drugs known to be narrow therapeutic index CYP3A4 substrates are excluded
• Drugs that are sensitive to CYP3A4 substrates are excluded
• Patients taking drugs that may further prolong QT intervals and present a known risk for Torsades de Pointes are excluded.
• Patients who have alcohol or drug dependence currently or in the last 6 months are excluded from this study
• Any other events, other than those defined above, in the opinion of the investigator, may make the patient ineligible for this trial
• No contraindication to biopsy such as bleeding disorders. Patients on anticoagulants such as warfarin must be able to safely stop the drug for a three-day period. Patients may not go on heparin during this time
• No active malignancy other than skin cancer or superficial bladder cancer
• Cardiac disease: congestive heart failure > class II NYHA. Patients must no have unstable angina or new onset angina or myocardial infarction within the past 6 months. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Patients must have an ejection fraction within normal limits at the enrolling institution based on an echocardiogram
• Uncontrolled hypertension defined as sustained BP > 160 and diastolic > 100 despite optimal medical management
• Known HIV or chronic Hep B or C
• Thrombolic or embolic events such as CVA within the last 6 months
• Pulmonary hemorrhage or any bleeding event CTCAE Grade 2 or greater within 6 months of first dose of study drug of KHAD
• Serious non-healing wound, ulcer, or bone fracture
• Evidence of history of bleeding diathesis or coagulopathy
• Major surgery or significant traumatic injury within 4 weeks of first study drug of KHAD

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.